Aclaris Therapeutics, Inc. (ACRS)Healthcare | Biotechnology | Wayne, United States | NasdaqGS
4.25 USD
+0.27
(6.784%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 4.24 -0.01 (-0.010%) ⇩ (April 17, 2026, 6:16 p.m. EDT) Short-term: ★★★☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 1:09 a.m. EDT
Aclaris is a polarizing high-risk biotech play: fundamental earnings are blended hard with the stock attempting a broad 70% recovery from the $1.09 low, yet a sharp 49% increase in short interest suggests market doubt at these levels. The data looks like a defensive mean-reversion setup with low options volume, betting that the intrinsic balance sheet (strong cash position) will survive the near-term clinical/earnings volatility. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.100264 |
| AutoETS | 0.100523 |
| MSTL | 0.146747 |
| AutoTheta | 0.215976 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.26 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.568 |
| Excess Kurtosis | -0.78 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.053 |
| Revenue per Share | 0.064 |
| Market Cap | 514,620,800 |
| Forward P/E | -5.62 |
| Beta | 0.68 |
| Website | https://www.aclaristx.com |
As of April 19, 2026, 1:09 a.m. EDT: Options gamma is extremely low (high IV ratios like 5.72 vs 1.98 for calls), suggesting a liquidity constrained or distressed market environment rather than high speculative flow. Call interest is heavily skewed toward near-term ATM (4.0/5.0 and 4.0/5.0 strikes), while put positioning is defensive and centered at lower strikes (1.0/3.0) with very thin volume, indicating a bid for downside value rather than active hedging. The negative adjusted predicted direction (-5.08%) contradicts the recent price strength, hinting at model pessimism regarding upcoming clinical data or earnings catalysts despite the 'strong buy' analyst consensus.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.761062 |
| Address1 | 701 Lee Road |
| Address2 | Suite 103 |
| All Time High | 33.88 |
| All Time Low | 0.59 |
| Ask | 5.17 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 1,294,860 |
| Average Daily Volume3 Month | 2,430,827 |
| Average Volume | 2,430,827 |
| Average Volume10Days | 1,294,860 |
| Beta | 0.679 |
| Bid | 4.24 |
| Bid Size | 1 |
| Board Risk | 9 |
| Book Value | 0.855 |
| City | Wayne |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.25 |
| Current Ratio | 3.362 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 4.27 |
| Day Low | 4.03 |
| Debt To Equity | 2.053 |
| Display Name | Aclaris Therapeutics |
| Earnings Call Timestamp End | 1,715,115,600 |
| Earnings Call Timestamp Start | 1,715,115,600 |
| Earnings Timestamp | 1,772,112,600 |
| Earnings Timestamp End | 1,778,157,000 |
| Earnings Timestamp Start | 1,778,157,000 |
| Ebitda | -74,035,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -5.726 |
| Enterprise To Revenue | 54.165 |
| Enterprise Value | 423,894,560 |
| Eps Current Year | -0.60167 |
| Eps Forward | -0.75571 |
| Eps Trailing Twelve Months | -0.53 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.5508 |
| Fifty Day Average Change | 0.6991999 |
| Fifty Day Average Change Percent | 0.19691335 |
| Fifty Two Week Change Percent | 276.1062 |
| Fifty Two Week High | 4.89 |
| Fifty Two Week High Change | -0.63999987 |
| Fifty Two Week High Change Percent | -0.13087933 |
| Fifty Two Week Low | 1.095 |
| Fifty Two Week Low Change | 3.155 |
| Fifty Two Week Low Change Percent | 2.8812785 |
| Fifty Two Week Range | 1.095 - 4.89 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,444,138,200,000 |
| Float Shares | 83,073,202 |
| Forward Eps | -0.75571 |
| Forward P E | -5.6238503 |
| Free Cashflow | -30,631,876 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 69 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Gross Profits | -52,103,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02568 |
| Held Percent Institutions | 0.84015 |
| Implied Shares Outstanding | 121,087,249 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. |
| Long Name | Aclaris Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 514,620,800 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_216879819 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -64,923,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 514,620,808 |
| Number Of Analyst Opinions | 8 |
| Open | 4.1 |
| Operating Cashflow | -47,113,000 |
| Operating Margins | -17.24633 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 484 324 7933 |
| Post Market Change | -0.010000229 |
| Post Market Change Percent | -0.2352995 |
| Post Market Price | 4.24 |
| Post Market Time | 1,776,464,217 |
| Previous Close | 3.98 |
| Price Eps Current Year | -7.0636725 |
| Price Hint | 4 |
| Price To Book | 4.9707603 |
| Price To Sales Trailing12 Months | 65.757835 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.362 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | 0.27 |
| Regular Market Change Percent | 6.78392 |
| Regular Market Day High | 4.27 |
| Regular Market Day Low | 4.03 |
| Regular Market Day Range | 4.03 - 4.27 |
| Regular Market Open | 4.1 |
| Regular Market Previous Close | 3.98 |
| Regular Market Price | 4.25 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 1,091,269 |
| Return On Assets | -0.24316 |
| Return On Equity | -0.50203997 |
| Revenue Growth | -0.859 |
| Revenue Per Share | 0.064 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 121,087,249 |
| Shares Percent Shares Out | 0.058000002 |
| Shares Short | 7,017,767 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 4,758,450 |
| Short Name | Aclaris Therapeutics, Inc. |
| Short Percent Of Float | 0.0678 |
| Short Ratio | 2.55 |
| Source Interval | 15 |
| State | PA |
| Symbol | ACRS |
| Target High Price | 16.0 |
| Target Low Price | 3.0 |
| Target Mean Price | 8.5 |
| Target Median Price | 7.5 |
| Total Cash | 90,751,000 |
| Total Cash Per Share | 0.753 |
| Total Debt | 2,116,000 |
| Total Revenue | 7,826,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.53 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.6282 |
| Two Hundred Day Average Change | 1.6218 |
| Two Hundred Day Average Change Percent | 0.6170763 |
| Type Disp | Equity |
| Volume | 1,091,269 |
| Website | https://www.aclaristx.com |
| Zip | 19,087 |